ArticleOncotarget2016
Troponin-I enhances and is required for oncogenic overgrowth.
Article in Oncotarget, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed.
- Troponin: biology, molecular mechanisms, and multidimensional clinical applications.Molecular biomedicine · 2026Review
- Pre-vaccine sentinel antibodies predict blunted vaccine responses.Cell press blue · 2026Article
- Cardiac Troponin I Promotes the Development of NSCLC Cells Through the Expression of Notch and Kras Proteins.Iranian journal of biotechnology · 2025Article
- Discovery and Characteristics of a Novel Antitumor Cyclopeptide Derived from Shark.Bioengineering (Basel, Switzerland) · 2023Article
- Overexpression of the PTEN Gene in Myocardial Tissues of Coronary Bypass Surgery Patients.Arquivos brasileiros de cardiologia · 2023Article
- Synaptic components are required for glioblastoma progression in Drosophila.PLoS genetics · 2022Article
- A role for Flower and cell death in controlling morphogen gradient scaling.Nature cell biology · 2022Article
- Circadian GeneInternational journal of molecular sciences · 2022Article
- Aberrant Expression of Cardiac Troponin-T in Lung Cancer Tissues in Association With Pathological Severity.Frontiers in cardiovascular medicine · 2022Article
- Molecular alterations in oral cancer using high-throughput proteomic analysis of formalin-fixed paraffin-embedded tissue.Journal of cell communication and signaling · 2021Article
- The haplolethality paradox of the wupA gene in Drosophila.PLoS genetics · 2021Article
- Emerging mechanisms of cell competition.Nature reviews. Genetics · 2020Review
- Characterization ofMolecules and cells · 2020Article
- An 8‑gene signature predicts the prognosis of cervical cancer following radiotherapy.Molecular medicine reports · 2019Article
- Drosophila Models of Cell Polarity and Cell Competition in Tumourigenesis.Advances in experimental medicine and biology · 2019Review
- Systemic signalling and local effectors in developmental stability, body symmetry, and size.Cell stress · 2018Review
- Troponin T3 associates with DNA consensus sequence that overlaps with p53 binding motifs.Experimental gerontology · 2018Article
- Troponin through the looking-glass: emerging roles beyond regulation of striated muscle contraction.Oncotarget · 2018Review
- Modelling Cooperative Tumorigenesis inBioMed research international · 2018Review
- Mechanisms of cell competition emerging from Drosophila studies.Current opinion in cell biology · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Human tumors of various tissue origins show an intriguing over-expression of genes not considered oncogenes, such as that encoding Troponin-I (TnI), a well-known muscle protein. Out of the three TnI genes known in humans, the slow form, TNNI1, is affected the most. Drosophila has only one TnI gene, wupA. Here, we studied excess- and loss-of function of wupA in Drosophila, and assayed TNNI1 down regulation in human tumors growing in mice. Drosophila TnI excess-of-function increases proliferation and potentiates oncogenic mutations in Ras, Notch and Lgl genes. By contrast, TnI loss-of-function reduces proliferation and antagonizes the overgrowth due to these oncogenic mutations. Troponin-I defective cells undergo Flower- and Sparc-dependent cell competition. TnI can localize to the nucleus and its excess elicits transcriptional up-regulation of InR, Rap1 and Dilp8, which is consistent with the increased cell proliferation. Human tumor cell lines treated with a human Troponin-I peptide arrest in G0/G1. In addition, proliferation of non-small-cell lung carcinoma xenografts in mice is restrained by TNNI1 down-regulation. Thus, Troponin-I reveals a novel function in cell proliferation that may be of therapeutic interest in certain types of cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.